Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,415JPY
22 Feb 2019
Change (% chg)

¥-25 (-0.56%)
Prev Close
¥4,440
Open
¥4,396
Day's High
¥4,435
Day's Low
¥4,373
Volume
5,918,400
Avg. Vol
10,370,225
52-wk High
¥6,221
52-wk Low
¥3,498

Chart for

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.77
Market Cap(Mil.): ¥6,909,497.00
Shares Outstanding(Mil.): 1,565.01
Dividend: 90.00
Yield (%): 4.08

Financials

  4502.T Industry Sector
P/E (TTM): 31.60 32.35 35.75
EPS (TTM): 139.72 -- --
ROI: 2.63 13.02 12.61
ROE: 5.32 14.07 13.81

U.S. jury orders Takeda to pay Bayer $155 million over hemophilia drug

A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

Feb 05 2019

UPDATE 1-U.S. jury orders Takeda to pay Bayer $155 mln over hemophilia drug

Feb 5 A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

Feb 05 2019

U.S. jury orders Takeda to pay Bayer $155 mln over hemophilia drug

Feb 5 A U.S. jury has ordered Takeda Pharmaceutical Co's Baxalta unit to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta hemophilia treatment, court records made public on Tuesday show.

Feb 05 2019

Olympics-Tokyo 2020 head says no need for Takeda to resign

TOKYO, Feb 1 Japanese Olympic Committee President Tsunekazu Takeda, being probed for suspected corruption, does not need to step down from his role with the Tokyo 2020 organising committee because current "reports" do not justify action, the head of Tokyo 2020 said.

Feb 01 2019

Takeda's third-quarter profit rises 28 percent on strong sales of main drugs

TOKYO Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

Feb 01 2019

UPDATE 1-Takeda's Q3 profit rises 28 pct on strong sales of main drugs

* Boosted by strong sales of bowel disease, multiple myeloma drugs (Adds sales details, divesting plans)

Feb 01 2019

Japan's Takeda posts 28 pct rise in Q3 operating profit

TOKYO, Feb 1 Takeda Pharmaceutical Co Ltd on Friday posted a 27.9 percent rise in third-quarter operating profit, supported by strong sales of its drugs for bowel disease and multiple myeloma.

Feb 01 2019

RPT-FOCUS-Bypassing U.S. regulators, Takeda takes its dengue shot to the tropics

CHICAGO, Jan 30 A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Jan 30 2019

RPT-FOCUS-Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

CHICAGO, Jan 30 A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Jan 30 2019

Undeterred by Sanofi's stumble, Takeda takes similar path with dengue shot

CHICAGO A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.

Jan 30 2019

Earnings vs. Estimates